Design of the Women's Health Initiative clinical trial and observational study

Controlled Clinical Trials

Volumn 19, Issue 1, 1998, Pages 61-109

  Anderson, G ^a   Cummings, S ^a   Freedman, L S ^a   Furberg, C ^a   Henderson, M ^a   Johnson, S R ^a   Kuller, L ^a   Manson, J ^a   Oberman, A ^a   Prentice, R L ^a   Rossouw , J E ^a   Finnegan, L ^a   Hiatt, R ^a   Pottern, L ^a   McGowan, J ^a   Clifford, C ^a   Caan, B ^a   Kipnis, V ^a   Ettinger, B ^a   Sidney, S ^a   Bailey, G ^a   LaCroix, A ^a   McTiernan, A ^a   Bowen, D ^a   Chen, C ^a   Cochrane, B ^a   Hunt, J ^a   Kristal, A ^a   Lund, B ^a   Patterson, R ^a   Probstfield, J ^a   Tinker, L ^a   Urban, N ^a   Wang, C Y ^a   White, E ^a   Kotchen, J M ^a   Shumaker, S ^a   Rautaharju, P ^a   Rautaharju, F ^a   Stein, E ^a   Laskarzewski, P ^a   Steiner, P ^a   Sagar, K ^a   Nevitt, M ^a   Dockrell, M ^a   Fuerst, T ^a   Himes, J ^a   Stevens, M ^a   Cammarata, F ^a   Lindenfelser, S ^a   Psaty, B ^a   Siscovick, D ^a   Longstreth, W ^a   Heckbert, S ^a   Wassertheil Smoller, S ^a   Frishman, W ^a   Wylie Rosett, J ^a   Barad, D ^a   Freeman, R ^a   Miller, S ^a   Hays, J ^a   Young, R ^a   Crowley, C ^a   DePoe, M A ^a   Burke, G ^a   Paskett, E ^a   Wagenknecht, L ^a   Crouse, R ^a   Parsons, L ^a   Kotchen, T ^a   Braunwald, E ^a   Buring, J ^a   Hennekens, C ^a   Gaziano, J M ^a   Assaf, A R ^a   Carleton, R ^a   Miller, M ^a   Wheeler, C ^a   Hume, A ^a   Pedersen, M ^a   Strickland, O ^a   Huber, M ^a   Porter, V ^a   Beresford, S ^a   Taylor, V ^a   Woods, N ^a   Hsia, J ^a   Barnabei, V ^a   Bovun, M ^a   Chlebowski, R ^a   Detrano, R ^a   Nelson, A ^a   Heiner, J ^a   Pushkin, S ^a   Valanis, B ^a   Stevens, V ^a   Whitlock, E ^a   Karanja, N ^a   Clark, A ^a   more..

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Calcium and vitamin D supplementation; Clinical trial monitoring; Cohort study; Dietary modification; Disease prevention; Hormone replacement therapy; Partial factorial design; Postmenopausal women; Randomized clinical trial; Study organization and management; Trial monitoring; Women's health

Indexed keywords

CALCIUM; VITAMIN D;

ADULT; AGED; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; EATING HABIT; FEMALE; HEALTH; HEALTH PROMOTION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LOW FAT DIET; METHODOLOGY; MORBIDITY; MORTALITY; NORMAL HUMAN; POSTMENOPAUSE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; RISK BENEFIT ANALYSIS;

EID: 6844255857     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(97)00078-0     Document Type: Article

References (117)

1. Rossouw JE, Finnegan CP, Harlan WRet al. The evolution of the Women's Health Initiative. perspectives from the NIH J Am Med Women's Assoc. 50:1995;50-55.
2. Insull W, Henderson MM, Prentice RLet al. Results of a randomized feasibility study of a low-fat diet. Arch Intern Med. 150:1990;421-427.
3. Henderson MM, Kushi LH, Thompson DJet al. Feasibility of a randomized trial of a low-fat diet for the prevention of breast cancer. dietary compliance in the Women's Health Trial Vanguard Study Prevent Med. 19:1990;115-133.
4. WHT:FSMP Investigator's Group The Women's Health Trial. Feasibility study in minority populations. Design and baseline descriptions Ann Epidemiol. 6:1996;507-519.
5. PEPI Trial Writing Group Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA. 273:1995;199-208.
6. PEPI Trial Writing Group Effects of hormone replacement therapy on endometrial histology in postmenopausal women. the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA. 275:1996;370-375.
7. PEPI Trial Writing Group Effects of hormone therapy on bone mineral density. results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA. 276:1996;1389-1396.
8. Doll R The lessons of life. keynote address to the nutrition and cancer conference Cancer Res. 52(suppl):1992;2024S-2029S.
9. Prentice RL, Kakar F, Hursting Set al. Aspects of the rationale for the Women's Health Trial. J Natl Cancer Inst. 80:1988;802-814.
10. Tannenbaum A Genesis and growth of tumors III. Effects of a high-fat diet. Cancer Res. 2:1942;468-475.
11. Carroll KK Experimental evidence of dietary factors and hormone-dependent cancers. Cancer Res. 35:1975;3374-3383.
12. Ip C, Carter CA Requirement of essential fatty acid for mammary tumorigenesis in the rat. Cancer Res. 451:1985;1997-2001.
13. Freedman L, Clifford C, Messina MW Analysis of dietary fat, calories, body weight, and the development of mammary tumors in rats and mice. a review Cancer Res. 40:1990;5710-5719.
14. Carroll KK, Braden LM Dietary fat and mammary carcinogenesis. Nutr Cancer. 6:1985;254-259.
15. Newberne PM, Schrager TE, Conner MW. Experimental evidence on the nutritional prevention of cancer. In: Moon TE, Micozzi MS, eds. Nutrition and Cancer Prevention: Investigating the Role of Micronutrients. New York: Marcel Dekker Inc, 1989, pp. 33-84.
16. Freedman LS, Clifford C Meta-analysis of animal experiments. elucidating relationships between dietary fat and mammary tumor development in rodents. In: Diet and Breast Cancer Advances in Experimental Medicine and Biology. 364:1994;93-100.
17. Henderson M. Correlations between fatty acid intake and cancer incidence. In: Nelson GH, ed. Health Effects of Dietary Fatty Acids. Champaign IL: American Oil Chemist's Society, 1991, pp. 136-149.
18. Zhao LP, Kushi LH, Klein RD, Prentice RL Quantitative review of studies of dietary fat and rat colon carcinoma. Nutr Cancer. 15:1991;169-177.
19. Goodwin PJ, Boyd NF Critical appraisal of the evidence that dietary fat is related to breast cancer risk in humans. J Natl Cancer Inst. 79:1987;473-485.
20. Rose DP, Boyar AP, Wynder EL International comparison of mortality rates of cancer of the breast, ovary, prostate and colon and per capita food consumption. Cancer. 58:1988;2363-2371.
21. Hursting S, Thornquist M, Henderson M Types of dietary fat and the incidence of breast cancer at five sites. Prev Med. 19:1990;242-253.
22. Prentice RL, Sheppard L Dietary fat and cancer. consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption Cancer Causes Contr. 1:1990;81-97.
23. Howe GR, Hirohata T, Hislop TGet al. Dietary factors and risk of breast cancer. combined analysis of 12 case-control studies J Natl Cancer Inst. 82:1990;561-569.
24. Hunter DJ, Spiegelman D, Adami H-Oet al. Cohort studies of fat intake and the risk of breast cancer. a pooled analysis N Engl J Med. 334:1996;356-361.
25. Howe GR, Aronson KJ, Benito Eet al. The relationship between dietary fat intake and risk of colorectal cancer. evidence from the combined analysis of 13 case-control studies Cancer Causes Contr. 8:1997;215-228.
26. Stemmerman GN, Nomura AMY, Heilbrun LK Dietary fat and the risk of colorectal cancer. Cancer Res. 44:1984;4633-4637.
27. Willett WC, Stampfer MJ, Colditz GAet al. Relation of meat, fat and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 323:1990;1664-1672.
28. Kolonel LN, Hankin JH, Nomura AMet al. Dietary fat intake and cancer incidence among five ethnic groups in Hawaii. Cancer Res. 41:1981;3727-3728.
29. McMichael AJ, Giles GG Cancer in migrants to Australia. extending the descriptive epidemiological data Cancer Res. 48:1988;751-756.
30. Ziegler RG, Hoover RN, Pike MCet al. Migrant patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 85:1993;1819-1827.
31. Kliewer EV, Smith KR Breast cancer mortality among immigrants in Australia and Canada. J Natl Cancer Inst. 87:1995;1154-1161.
32. Willett WC, Sampson L, Stampfer MJet al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 122:1985;51-65.
33. Lichtman SW, Pisarka K, Berman ERet al. Discrepancy between self-reported and actual calorie intake and exercise in obese subjects. N Engl J Med. 327:1992;1893-1898.
34. Heitmann BL, Lessner L Dietary underreporting by obese individuals. is it specific or nonspecific? Br Med J. 311:1995;986-989.
35. Prentice RL Measurement error and results from analytic epidemiology. dietary fat and breast cancer J Natl Cancer Inst. 88:1996;1738-1747.
36. White E, Shattuck A, Kristal Aet al. Maintenance of a low-fat diet. follow-up of the Women's Health Trial Cancer Epidemiol Biomark Prev. 1:1992;315-323.
37. Boyd NF, Martin LJ, Beaton Met al. Long-term effects of participation in a randomized trial of a low-fat, high-carbohydrate diet. Cancer Epidemiol Biomark Prev. 5:1996;217-222.
38. Greenwald P, Lanza E, Eddy G Dietary fiber in the reduction of colon cancer risk. J Am Diet Assoc. 87:1987;1178-1188.
39. Trock BJ, Lanza E, Greenwald P. High-fiber diet and colon cancer: a critical review. In: Mettlin CJ, Aoki K, eds. Recent Progress in Research on Nutrition and Cancer. Progress in Clinical and Biological Research, 1990;346:145-158.
40. Howe GR, Benito E, Castelleto Ret al. Dietary intake of fiber and decreased risk of cancer of the colon and rectum. evidence from the combined analysis of 13 case-control studies J Natl Cancer Inst. 84:1992;1887-1896.
41. Keys A. Seven Countries: A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
42. Robertson TL, Kato H, Gordon Tet al. Epidemiologic studies in coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California. incidence of myocardial infarction and death from coronary heart disease Am J Cardiol. 239:1977;244-249.
43. Ernst N, Fisher M, Bowen P, Schaefer EJet al. Changes in plasma lipids and lipoproteins after a modified fat diet. Lancet. 2:1980;111-113.
44. Kris-Etherton PM, Krummel D, Russell MEet al. The effect of diet on plasma lipids, lipoproteins, and coronary heart disease. J Am Diet Assoc. 88:1988;1373-1400.
45. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
46. Frick MH, Elo O, Haapa Ket al. Helsinki Heart Study. primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med. 317:1987;1237-1245.
47. Scandinavian Simvastatin Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S) Lancet. 344:1994;1383-1389.
48. Tinker LF, Burrows ER, Henry H, et al. The Women's Health Initiative: overview of the nutrition components. In: Krummel DA, Kris-Etherton PM, eds. Nutrition in Women's Health. Gaithersburg, MD: Aspen Publishers, 1996, pp. 510-542.
49. Canner PL, Berge KG, Wenger NKet al. Fifteen-year mortality in Coronary Drug Project patients. long-term benefit with niacin J Am Coll Cardio. 8:1986;1245-1255.
50. Sotaniemi EA, Kontturi MJ Serum lipid levels and thromboembolic complications during estrogen therapy of prostatic cancer. Scand J Urol Nephrol. 9:1975;89-93.
51. Petitti DB, Wingerd J, Pellegrin Fet al. Risk of vascular disease in women. smoking and oral contraceptives, noncontraceptive estrogens, and other factors JAMA. 242:1979;1150-1154.
52. Barrett-Connor E, Bush TL Estrogen and coronary heart disease in women. JAMA. 265:1991;1861-1867.
53. Korneman GS, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, MA: Serono Symposia, 1990, pp. 211-224.
54. Godsland IF, Wynn V, Crook Det al. Sex, plasma lipoproteins, and atherosclerosis. prevailing assumptions and outstanding questions Am Heart J. 114:1987;1467-1503.
55. Matthews KA, Meilahn E, Kuller LHet al. Menopause and risk factors for coronary heart disease. N Engl J Med. 321:1989;641-646.
56. Stampfer MJ, Colditz GA Estrogen replacement therapy and coronary heart disease. a quantitative assessment of the epidemiologic evidence Prev Med. 20:1991;47-63.
57. Grady D, Rubin SM, Petitti DBet al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1036.
58. Henderson BE, Paganini-Hill A, Ross RK Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 151:1991;75-78.
59. Bush TL, Barrett-Connor E, Cowan LDet al. Cardiovascular mortality and noncontraceptive use of estrogen in women. results from the Lipid Research Clinics Program Follow-up Study Circulation. 75:1987;1102-1109.
60. Nachtigall LE, Nachtigall RH, Nachtigall RDet al. Estrogen replacement therapy II. a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems Obstet Gynecol. 54:1979;74-79.
61. Rijpkema AHM, van der Sanden AA, Ruijs AHC Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins. a review Maturitas. 12:1990;259-285.
62. Walsh BW, Schiff I, Rosner Bet al. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med. 325:1991;1196-1204.
63. Lieberman EH, Gerhard MD, Uehata Aet al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
64. Hemminki E, Sihvo S A review of postmenopausal hormone therapy recommendations. potential for selection bias Obstet Gynecol. 82:1993;1021-1028.
65. Cauley JA, Cummings SR, Black DMet al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 163:1990;1438-1444.
66. Espeland MA, Applegate W, Furberg CDet al. for the ACAPS Investigators. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Amer J Epid. 142:1995;1011-1019.
67. Stampfer MJ, Colditz GA, Willett WCet al. Postmenopausal estrogen therapy and cardiovascular disease. ten-year follow-up from the Nurses' Health Study N Engl J Med. 325:1991;756-792.
68. Persson I, Adami H-O, Bergkvist Let al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens. results of a prospective study Br Med J. 298:1989;147-151.
69. Goldman L, Tosteson ANA Uncertainty about postmenopausal estrogen. time for action, not debate N Engl J Med. 325:1991;800-802.
70. Psaty BM, Heckbert SR, Atkins Det al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 153:1993;1421-1427.
71. Felson DT, Zhang Y, Hannan MTet al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 329:1993;1141-1146.
72. Cauley JA, Seeley DG, Ensrud Ket al. for the study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 122:1995;9-16.
73. Fleisch H New bisphosphonates in osteoporosis. Osteoporosis Inc. 2:1993;S15-S22.
74. Steinberg KK, Thacker SB, Smith SJet al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 265:1991;1985-1990.
75. Dupont WD, Page DL Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 151:1991;67-72.
76. Bergkvist L, Adami H-O, Persson Iet al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 321:1989;293-297.
77. Colditz GA, Hankinson SE, Hunter DJet al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1995;1589-1593.
78. Stanford JL, Weiss NS, Voigt Let al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 274:1995;137-142.
79. Lobo RA, Pickar JH, Wild RAet al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 84:1994;987-995. for the Menopause Study Group.
80. Wysowski DK, Golden L, Burke L Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-92. Obstet Gynecol. 85:1995;6-10.
81. Lindsay R, Hart DM, Clark DM The minimum effective dose of estrogen for preventing postmenopausal bone loss. Obstet Gynecol. 63:1984;759-763.
82. Whitehead MI, Hillard TC, Crook D The role and use of progestogens. Obstet Gynecol. 75:1990;59S-76S.
83. Ferguson KJ, Hoegh C, Johnson SR Estrogen replacement therapy. a survey of women's knowledge and attitudes Arch Int Med. 149:1989;133-136.
84. Cummings SR, Black DM, Rubin SM Lifetime risks of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 149:1989;2445-2448.
85. Cummings SR, Black DM, Nevitt MCet al. Bone density at various sites for prediction of hip fractures. Lancet. 341:1993;72-75.
86. Heaney RP, Recker RR Distribution of calcium absorption in middle-aged women. Am J Clin Nutr. 43:1986;299-305.
87. Heaney RP, Recker RR, Stegman MRet al. Calcium absorption in women. relationships to calcium intake, estrogen status, and age J Bone Miner Res. 4:1989;469-475.
88. Peck WA, Burckhardt P, Christiansen C, et al. Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-650.
89. Alaimo K, McDowell MA, Briefel RRet al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States. Third National Health and Nutrition Examination Survey, Phase 1, 1988-91 Advance Data. 14:1994;1-28.
90. Cumming RG Calcium intake and bone mass. a quantitative review of the evidence Calcif Tissue Int. 47:1990;194-201.
91. Dawson-Hughes B Calcium supplementation and bone loss. a review of controlled clinical trials Am J Clin Nutr. 54:1991;274S-280S.
92. Holbrook TL, Barrett-Connor E, Wingard DL. Dietary calcium and risk of hip fracture: 14-year prospective population study. Lancet 1988;1046-1049.
93. Paganini-Hill A, Chao A, Ross RKet al. Exercise and other factors in the prevention of hip fracture. the Leisure World Study Epidemiology. 2:1991;16-25.
94. Dawson-Hughes B, Dallal GE, Krall EAet al. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Ann Intern Med. 115:1991;505-512.
95. Heikinheimo RJ, Inkovaara JA, Harju EJet al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int. 51:1992;105-110.
96. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 327:1992;1637-1642.
97. Seeley DG, Browner WS, Nevitt MCet al. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med. 115:1991;837-842.
98. Lipkin M, Newmark H Effect of added dietary calcium on colonic epithelial proliferation in subjects at high risk for familial colon cancer. N Engl J Med. 313:1985;1381-1384.
99. Garland C, Shekelle RB, Barrett-Connor Eet al. Dietary vitamin D and calcium and risk of colorectal cancer. a 19-year prospective study in men Lancet. 1:1985;307-309.
100. Slattery M, Sorenson A, Ford M Dietary calcium intake as a mitigating factor in colon cancer. Am J Epidemiol. 128:1988;504-514.
101. Bostick R, Potter JD, Sellers TAet al. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. the Iowa Women's Health Study Am J Epidemiol. 137:1993;1302-1317.
102. Jain M, Cook GM, Davis FGet al. A case-control study of diet and colorectal cancer. Int J Cancer. 26:1980;757-768.
103. Kampman E, Giovannucci E, van't Veer Pet al. Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol. 139:1994;16-29.
104. Garland C, Comstock G, Garland Fet al. Serum 25-hydroxyvitamin D and colon cancer. eight-year prospective study Lancet. 2:1989;1176-1178.
105. Braun MM, Helzlsouer KJ, Hollis BWet al. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol. 142:1995;608-611.
106. Eisman JA, Martin TJ, MacIntyre Iet al. 1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet. 2:1979;1335-1336.
107. Bower M, Colston KW, Stein RCet al. Topical calcipotriol treatment in advanced breast cancer. Lancet. 337:1991;701-702.
108. Gorham ED, Garland FC, Garland CF Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 19:1990;820-824.
109. Garland FC, Garland CF, Gorham EDet al. Geographic variation in breast cancer mortality in the United States. a hypothesis involving exposure to solar radiation Prev Med. 19:1990;614-622.
110. Curhan GC, Willett WC, Rimm EBet al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 328:1993;833-838.
111. Jacobs D, Blackburn H, Higgins Met al. Report on the conference on low blood cholesterol. mortality associations Circulation. 86:1992;1046-1060.
112. Self S, Prentice R, Iverson Det al. Statistical design of the Women's Health Trial. Controlled Clin Trials. 9:1988;119-136.
113. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 2: The Design and Analysis of Cohort Studies. Lyon, France: IARC Scientific Publication No. 82, International Agency for Research on Cancer; 1987.
114. Prentice RL Design issues in cohort studies. Stat Meth Med Res. 4:1995;273-292.
115. McTiernan A, Rossouw JR, Manson Jet al. Informed consent in the Women's Health Initiative clinical trial and observational study. J Women's Health. 5:1996;519-529.
116. Freedman LS, Anderson G, Kipnis Vet al. Approaches to monitoring the results of long-term disease prevention trials. examples from the Women's Health Initiative Controlled Clin Trials. 17:1996;509-525.
117. O'Brien PC, Fleming RT A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.